CorMedix Inc (CRMD)

Currency in USD
5.270
+0.190(+3.74%)
Closed·
5.380+0.110(+2.09%)
·
CRMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.9505.315
52 wk Range
4.46513.020
Key Statistics
Prev. Close
5.27
Open
4.96
Day's Range
4.95-5.315
52 wk Range
4.465-13.02
Volume
3.61M
Average Volume (3m)
1.44M
1-Year Change
-45.5579%
Book Value / Share
5.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.800
Upside
+161.86%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

CorMedix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.800
(+161.86% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy14.00+165.65%15.00Maintain13/11/2026
Oppenheimer
Buy13.00+146.68%15.00Maintain13/11/2026
RBC Capital
Buy15.00+184.63%14.00Maintain10/11/2026
Needham
Buy14.00+165.65%12.00Maintain10/11/2026
Citizens
Buy19.00+260.53%-Maintain10/11/2026

CorMedix Inc SWOT Analysis


Strategic Acquisition
CorMedix's $300M acquisition of Melinta Therapeutics promises portfolio diversification and near-term EPS accretion, reshaping its market position
Financial Projections
Explore CorMedix's ambitious FY2025 guidance, projecting revenues of $305M-$330M and EBITDA of $150M-$170M, signaling strong growth potential
DefenCath's Momentum
Delve into DefenCath's Q2 2025 sales of $39M and its potential expansion into the TPN market, highlighting CorMedix's focus on product development
Analyst Outlook
Citizens Bank sets a $22 price target for CRMD, labeling it "MARKET OUTPERFORM" and underscoring the stock's potential upside
Read full SWOT analysis

CorMedix Inc Earnings Call Summary for Q3/2026

  • Q3 revenue hit $54.5M, beating estimates by 2.3% but down 47.8% YoY; loss widened to $0.19/share vs. $0.10 forecast amid DefenCath reimbursement shift.
  • DefenCath sales fell sharply to $17.2M after TDAPA program ended July 1; CMS set Q1 2027 add-on at $8.32, expected to at least double current $2.37 rate.
  • CorMedix reaffirmed 2026 guidance of $325M-$345M revenue and $130M-$140M adjusted EBITDA; operating expenses narrowed to $140M-$145M range.
  • Heron acquisition expected to close Q1 2027, immediately accretive to earnings; REZZAYO prophylaxis launch possible in 2027 pending FDA priority review.
  • Company holds $355.2M cash with strong liquidity ratio of 2.56; pursuing Medicare Advantage contracts and TPN trial expansion despite enrollment delays.
Last Updated: 13/11/2026, 01:46 am
Read Full Transcript

Earnings

Latest Release
12/11/2026
EPS / Forecast
-0.19 / -0.10
Revenue / Forecast
54.5M / 53.27M
EPS Revisions
Last 90 days

CRMD Income Statement

Compare CRMD to Peers and Sector

Metrics to compare
CRMD
Peers
Sector
Relationship
P/E Ratio
6.6x−1.5x−0.2x
PEG Ratio
−0.10−0.290.00
Price/Book
0.9x2.2x2.6x
Price / LTM Sales
1.0x1.4x2.6x
Upside (Analyst Target)
161.9%130.9%77.0%
Fair Value Upside
Unlock16.3%13.7%Unlock

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Employees
191

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
20.69M26.01%109.02M
Other Institutional Investors
31.89M40.09%168.06M
Public Companies & Retail Investors
26.96M33.90%142.09M
Total
79.54M100.00%419.16M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.11%6,453,15434,008
Deep Track Capital, LP7.89%6,274,07633,064

People Also Watch

54.430
LQDA
-3.88%
1,082.0
WIZZ
-1.81%
0.339
OHLA
-2.87%
4.2300
APE
-4.73%

FAQ

What Is the CorMedix (CRMD) Stock Price Today?

The CorMedix stock price today is 5.270 USD.

What Stock Exchange Does CorMedix Trade On?

CorMedix is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for CorMedix?

The stock symbol for CorMedix is "CRMD."

What Is the CorMedix Market Cap?

As of today, CorMedix market cap is 419.160M USD.

What Is CorMedix's Earnings Per Share (TTM)?

The CorMedix EPS (TTM) is 0.81.

When Is the Next CorMedix Earnings Date?

CorMedix will release its next earnings report on 30/03/2027.

From a Technical Analysis Perspective, Is CRMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CorMedix Stock Split?

CorMedix has split 1 times.

How Many Employees Does CorMedix Have?

CorMedix has 191 employees.

What is the current trading status of CorMedix (CRMD)?

As of 22/11/2026, CorMedix (CRMD) is trading at a price of 5.270 USD, with a previous close of 5.270 USD. The stock has fluctuated within a day range of 4.950 USD to 5.315 USD, while its 52-week range spans from 4.465 USD to 13.020 USD.

What Is CorMedix (CRMD) Price Target According to Analysts?

The average 12-month price target for CorMedix is 13.800 USD, with a high estimate of 17 USD and a low estimate of 12 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +161.86% Upside potential.

What Is the CRMD Premarket Price?

CRMD's last pre-market stock price is 5.070 USD. The pre-market share volume is 1,450.000, and the stock has decreased by -0.010, or -0.200%.

What Is the CRMD After Hours Price?

CRMD's last after hours stock price is 5.380 USD, the stock has decreased by 0.110, or 2.090%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.